Peptides like BPC-157 and GHK-Cu have become increasingly popular for their potential role in healing, recovery, and regeneration.
But what do they actually do, and why aren’t they FDA approved?
BPC-157 is a peptide originally identified in gastric tissue. It appears to work through pathways involving vascular endothelial growth factor (VEGF) and nitric oxide. These pathways play a key role in blood vessel formation, tissue repair, and healing.
Preclinical studies have shown promising effects in tendon healing, ligament repair, and protection of the gastrointestinal lining. Early human data, including small studies in ulcerative colitis, suggested potential benefit with minimal reported side effects.
However, large-scale, FDA-level clinical trials do not exist.
GHK-Cu is a naturally occurring tripeptide found in human plasma. Its levels decline with age. It has been studied for its role in collagen production, skin thickness, wound healing, and antioxidant activity.
GHK-Cu is already widely used in topical skincare and wound care products, where it has a strong safety profile and supportive data.
The injectable form is being used for systemic effects, but it is less well studied compared to topical use.
So why haven’t these peptides been approved?
The answer is not simply that they don’t work.
Drug development requires massive investment, long timelines, and strong patent protection. Many peptides are difficult to patent in a way that allows a company to justify spending hundreds of millions of dollars on clinical trials.
In the case of BPC-157, existing patents have a limited lifespan. Without long-term exclusivity, there is little financial incentive to fund large trials.
This creates a situation where promising compounds exist but do not move through the traditional drug development pathway.
That does not mean they are ineffective. It means they have not been formally validated through FDA-level trials.
The real issue patients need to understand is not just the science, but the sourcing.
Many people are obtaining these peptides through online vendors selling “research use only” products. These are not regulated medications. They are not required to meet sterility standards. They are not verified for purity or dosing accuracy.
Injecting these products carries real risk.
Peptides like BPC-157 and GHK-Cu are biologically active and potentially beneficial, but they should not be treated casually.
They are not supplements.
They require proper sourcing, appropriate dosing, and medical oversight.
The bottom line is simple.
There is promising science.
There are real limitations in data.
And there is a huge difference between physician-guided therapy and unregulated use.
That difference is what determines safety.
References
- Sikiric P et al. BPC-157 and wound healing. Current Pharmaceutical Design. 2018.
- Pickart L. The human tripeptide GHK and tissue remodeling. Journal of Biomaterials Science. 2008.
- Lau JL, Dunn MK. Therapeutic peptides: historical perspectives. Bioorganic & Medicinal Chemistry. 2018.
- DiMasi JA et al. Cost of drug development. Journal of Health Economics. 2016.
- U.S. FDA. Compounding and bulk substances guidance.
